Fig. 3: Comparative evaluation of SHGS against 13 senescence and aging-related gene signatures across MASLD cohorts. | Nature Communications

Fig. 3: Comparative evaluation of SHGS against 13 senescence and aging-related gene signatures across MASLD cohorts.

From: Targeting senescent hepatocytes for treatment of metabolic dysfunction-associated steatotic liver disease and multi-organ dysfunction

Fig. 3

A Gene set size comparison showing SHGS as a relatively small gene set compared to 13 other senescence- and aging-related signatures. B Jaccard similarity matrix illustrating pairwise overlap among 14 gene signatures, with SHGS showing minimal overlap with others, emphasizing its unique composition. C–J Heatmaps of AUC values for SHGS and other gene signatures across MASLD datasets: C from GSE49541 (F3/F4 vs F0/F1), D–F from GSE213621 (MASLD vs Control, F3/F4 vs Control, and F3/F4 vs F0/F1), G–I from the Germany cohort GSE33814 (MASLD vs Control, MASH vs Control, and MASH vs MAFL), and (J) from the Japan cohort GSE167523 (MASH vs MASLD). These comparisons demonstrate SHGS’s predictive performance across diverse datasets. K Boxplot summarizing AUC rankings for SHGS and other gene signatures across eight comparisons. Each point represents the rank of a specific signature within a dataset, with boxplots display the upper quantile (75%), median (50%), and lower quantile (25%) of overall data distribution. SHGS ranks highest in four comparisons, second in two, and fourth or fifth in the remaining two, highlighting its superior and consistent performance.

Back to article page